Surgical efficacy and quality of wide resection of the pelvic peritoneum in patients with epithelial ovarian cancer.

[1]  H. Katabuchi,et al.  Angiopoietin-like protein 2 decreases peritoneal metastasis of ovarian cancer cells by suppressing anoikis resistance. , 2021, Biochemical and biophysical research communications.

[2]  Christer S. Ejsing,et al.  Adipocyte-like signature in ovarian cancer minimal residual disease identifies metabolic vulnerabilities of tumor-initiating cells , 2021, JCI insight.

[3]  A. Bhatt,et al.  Total parietal peritonectomy performed during interval cytoreductive surgery for advanced epithelial serous ovarian cancer results in a low incidence of platinum resistant recurrence- results of a prospective multi-centre study. , 2021, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[4]  H. Katabuchi,et al.  The Hallmarks of Ovarian Cancer Stem Cells and Niches: Exploring Their Harmonious Interplay in Therapy Resistance. , 2021, Seminars in cancer biology.

[5]  H. Katabuchi,et al.  Omental metastasis as a predictive risk factor for unfavorable prognosis in patients with stage III–IV epithelial ovarian cancer , 2021, International Journal of Clinical Oncology.

[6]  E. Lengyel,et al.  Updates and New Options in Advanced Epithelial Ovarian Cancer Treatment , 2020, Obstetrics and gynecology.

[7]  S. Ye,et al.  Total pelvic peritonectomy for ovarian cancer with extensive peritoneal carcinomatosis in pelvic cavity. , 2019, Gynecologic Oncology.

[8]  G. Mehta,et al.  The Role of Cancer Stem Cells and Mechanical Forces in Ovarian Cancer Metastasis , 2019, Cancers.

[9]  H. Katabuchi,et al.  Ovarian Cancer Stemness: Biological and Clinical Implications for Metastasis and Chemotherapy Resistance , 2019, Cancers.

[10]  A. Oza,et al.  Epithelial ovarian cancer , 2019, The Lancet.

[11]  Zhiyuan Hu,et al.  An evolving story of the metastatic voyage of ovarian cancer cells: cellular and molecular orchestration of the adipose-rich metastatic microenvironment , 2018, Oncogene.

[12]  Ita Novita Sari,et al.  Cancer Stem Cells (CSCs) in Drug Resistance and their Therapeutic Implications in Cancer Treatment , 2018, Stem cells international.

[13]  A. Okamoto,et al.  Retrospective analysis of sites of recurrence in stage I epithelial ovarian cancer , 2018, Journal of gynecologic oncology.

[14]  A. D. De Rose,et al.  Hepatoceliac Lymph Node Involvement in Advanced Ovarian Cancer Patients: Prognostic Role and Clinical Considerations , 2017, Annals of Surgical Oncology.

[15]  H. Saya,et al.  The impact of EpCAM expression on response to chemotherapy and clinical outcomes in patients with epithelial ovarian cancer , 2017, Oncotarget.

[16]  R. Tozzi,et al.  En-bloc resection of the pelvis (EnBRP) in patients with stage IIIC-IV ovarian cancer: A 10 steps standardised technique. Surgical and survival outcomes of primary vs. interval surgery. , 2017, Gynecologic oncology.

[17]  D. F. Chedom,et al.  Salt-Inducible Kinase 2 Couples Ovarian Cancer Cell Metabolism with Survival at the Adipocyte-Rich Metastatic Niche. , 2016, Cancer cell.

[18]  H. Katabuchi,et al.  CD44 Variant 6 as a Predictive Biomarker for Distant Metastasis in Patients With Epithelial Ovarian Cancer , 2016, Obstetrics and gynecology.

[19]  H. Katabuchi,et al.  CD44 variant 6 is correlated with peritoneal dissemination and poor prognosis in patients with advanced epithelial ovarian cancer , 2015, Cancer science.

[20]  Stephen T. C. Wong,et al.  Cellular and molecular processes in ovarian cancer metastasis. A Review in the Theme: Cell and Molecular Processes in Cancer Metastasis. , 2015, American journal of physiology. Cell physiology.

[21]  Z. Werb,et al.  The cancer stem cell niche: how essential is the niche in regulating stemness of tumor cells? , 2015, Cell stem cell.

[22]  G. Scambia,et al.  Mesenteric Lymph Node Involvement in Advanced Ovarian Cancer Patients Undergoing Rectosigmoid Resection: Prognostic Role and Clinical Considerations , 2014, Annals of Surgical Oncology.

[23]  Jaime Prat,et al.  Staging classification for cancer of the ovary, fallopian tube, and peritoneum , 2014, International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics.

[24]  H. Kajiyama,et al.  Functional interaction between peritoneal mesothelial cells and stem cells of ovarian yolk sac tumor (SC-OYST) in peritoneal dissemination. , 2012, Gynecologic oncology.

[25]  G. Scambia,et al.  Douglas peritonectomy compared to recto-sigmoid resection in optimally cytoreduced advanced ovarian cancer patients: analysis of morbidity and oncological outcome. , 2011, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[26]  N. Onishi,et al.  Transient depletion of p53 followed by transduction of c-Myc and K-Ras converts ovarian stem-like cells into tumor-initiating cells. , 2011, Carcinogenesis.

[27]  Jacobus Pfisterer,et al.  Role of surgical outcome as prognostic factor in advanced epithelial ovarian cancer: A combined exploratory analysis of 3 prospectively randomized phase 3 multicenter trials , 2009, Cancer.

[28]  R. Barakat,et al.  Pelvic cytoreduction with rectosigmoid resection. , 2007, Gynecologic Oncology.

[29]  W. Cliby,et al.  Role of rectosigmoidectomy and stripping of pelvic peritoneum in outcomes of patients with advanced ovarian cancer. , 2006, Journal of the American College of Surgeons.

[30]  He-jing Wang,et al.  Complete cytoreductive surgery is feasible and maximizes survival in patients with advanced epithelial ovarian cancer: a prospective study. , 1998, Gynecologic oncology.

[31]  P. Grambsch,et al.  Proportional hazards tests and diagnostics based on weighted residuals , 1994 .

[32]  N. Hacker,et al.  Rectosigmoid Colectomy and Reanastomosis to Facilitate Resection of Primary and Recurrent Gynecologic Cancer , 1984, Obstetrics and gynecology.

[33]  C. N. Hudson.  A RADICAL OPERATION FOR FIXED OVARIAN TUMOURS , 1968, The Journal of obstetrics and gynaecology of the British Commonwealth.

[34]  H. Ryu,et al.  Impact of Complete Cytoreduction Leaving No Gross Residual Disease Associated with Radical Cytoreductive Surgical Procedures on Survival in Advanced Ovarian Cancer , 2012, Annals of Surgical Oncology.

[35]  H. Katabuchi,et al.  Pathophysiological dynamics of human ovarian surface epithelial cells in epithelial ovarian carcinogenesis. , 2005, International review of cytology.

[36]  P. Sugarbaker.  Complete parietal and visceral peritonectomy of the pelvis for advanced primary and recurrent ovarian cancer. , 1996, Cancer treatment and research.

[37]  R. Schofield.  The relationship between the spleen colony-forming cell and the haemopoietic stem cell. , 1978, Blood cells.

[38]  C. Griffiths.  Surgical resection of tumor bulk in the primary treatment of ovarian carcinoma. , 1975, National Cancer Institute monograph.